Tight Glycemic Control by Artificial Pancreas

Verified by: Kochi University, April 2008
First Received: April 4, 2008 | Last Updated: April 8, 2008 | Phase: N/A | Start Date: April 2007
Overall Status: Completed | Estimated Enrollment: 32
  • …
  • Tell a FriendPrint

This study evaluated a closed-loop system providing continuous monitoring and strict control of perioperative blood glucose following pancreatic resection...

Brief Summary

Official Title: “Continuous Postoperative Blood Glucose Monitoring and Control by an Artificial Pancreas in Patients Undergoing Pancreatic Resection: A Prospective Randomized Clinical Trial”

This study evaluated a closed-loop system providing continuous monitoring and strict control of perioperative blood glucose following pancreatic resection.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
  • Study Primary Completion Date: December 2007

Detailed Clinical Trial Description

This study recruited 32 patients undergoing elective pancreatic resection for pancreatic disease.

Intervention(s) in this Clinical Trial

  • Device: Artificial Pancreas (STG-22)
    • safe tool

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: 2
    • Thirty patients who underwent pancreatic resection for pancreatic neoplasm were prospectively randomized. Perioperative blood glucose levels were continuously monitored using an artificial endocrine pancreas (STG-22). Glucose levels were controlled using either the sliding scale method or the artificial pancreas.

Outcome Measures for this Clinical Trial

Primary Measures

  • the incidence of severe hypoglycemia (< 40 mg/dl) during the intensive care period following pancreatic resection in patients monitored using the artificial pancreas
    • Time Frame: the first postoperative 18 hours in the surgical intensive care unit
      Safety Issue?: Yes

Secondary Measures

  • the total amount of insulin required for glycemic control after pancreatic resection
    • Time Frame: the first postoperative 18 hours in the surgical intensive care unit
      Safety Issue?: Yes

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • This study recruited 32 patients undergoing elective pancreatic resection for pancreatic disease.

Exclusion Criteria:

  • weight loss greater than 10% during the previous 6 months
  • signs of distant metastasis
  • respiratory, renal,or heart disease
  • Patients provided written informed consent prior to enrollment

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: N/A

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: Kochi University Other

Overall Clinical Trial Officials and Contacts

Takehiro Okabayashi, MD Study Director Kochi Medical School, Kochi University  

Additional Information

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00657995

Study ID Number: TGC-AP-01

ClinicalTrials.gov Identifier: NCT00657995

Health Authority: Japan: Ministry of Education, Culture, Sports, Science and Technology

  • …
  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00657995